Mar 3, 2025 07:01AM

Mar 3, 2025 07:00AM

Feb 28, 2025 07:00AM

Feb 18, 2025 07:00AM

Nov 15, 2024 07:01AM

Nov 15, 2024 07:00AM

Oct 8, 2024 07:01AM Opthea (OPT) announced three senior hires

Oct 8, 2024 07:00AM

Sep 23, 2024 07:00AM

Sep 18, 2024 07:30AM

Sep 18, 2024 07:30AM

Sep 5, 2024 06:11AM

Sep 5, 2024 06:00AM

Aug 30, 2024 07:30AM Opthea Reports Full-Year Financial Results and Business Updates

Jul 17, 2024 07:16AM

Jul 17, 2024 07:15AM

Jul 9, 2024 07:30AM

Jun 18, 2024 08:57PM

Jun 13, 2024 07:58PM

Jun 11, 2024 09:13PM

May 28, 2024 07:30AM Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Apr 3, 2024 05:41PM

Apr 3, 2024 05:39PM

Mar 19, 2024 06:00AM

Feb 28, 2024 05:55PM

Feb 14, 2024 07:00AM

Feb 1, 2024 06:02AM

Feb 1, 2024 06:00AM Opthea Strengthens Team with Key Clinical and Regulatory Hires

Feb 13, 2023 06:01AM

Feb 13, 2023 06:00AM

Oct 19, 2021 06:00AM

Oct 4, 2021 07:00AM

Aug 30, 2021 07:00AM

Aug 9, 2021 07:00AM

Jul 15, 2021 09:00AM Oppenheimer Remains Bullish on Opthea Ltd. (OPT) Following FDA Fast Track Designation

Jul 6, 2021 07:00AM

Mar 31, 2021 05:30AM

Mar 15, 2021 05:30AM

Feb 24, 2021 05:30AM

Aug 21, 2020 05:30AM

Mar 7, 2019 05:30AM

Jan 29, 2019 11:25AM Opthea Granted Japanese Patent Covering OPT-302

Nov 26, 2018 11:32AM

Nov 14, 2018 05:30AM

Oct 29, 2018 05:30AM

Oct 26, 2018 05:30AM

Oct 24, 2018 05:30AM

Sep 24, 2018 05:30AM

Sep 14, 2018 05:30AM Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the Retina Society 2018 Annual Meeting

Sep 5, 2018 05:30AM

322,185 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All